Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Oncotarget

Volumn 5, Issue 3, 2014, Pages 587-598

  Li, Huili ^a   Chiappinelli, Katherine B ^a   Guzzetta, Angela A ^a   Easwaran, Hariharan ^a   Yen, Ray Whay Chiu ^a   Vatapalli, Rajita ^a   Topper, Michael J ^a   Luo, Jianjun ^a   Connolly, Roisin M ^a   Azad, Nilofer S ^a   Stearns, Vered ^a   Pardoll, Drew M ^a   Davidson, Nancy ^b   Jones, Peter A ^c   Slamon, Dennis J ^d   Baylin, Stephen B ^a   Zahnow, Cynthia A ^a   Ahuja, Nita ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen processing; Cancers; DNA methyltransferase inhibitor; Epigenetics; Immune; Interferon; Methylation

Indexed keywords

AZACITIDINE; CANCER TESTIS ANTIGEN; CARBOPLATIN; ENTINOSTAT; HLA C ANTIGEN; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 15; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; RETINOIC ACID INDUCIBLE PROTEIN I; DNA; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD274 GENE; COLORECTAL CANCER; CONTROLLED STUDY; DDX58 GENE; DNA METHYLATION; DOSE RESPONSE; GENE; GENE CLUSTER; GENE EXPRESSION REGULATION; HLA C GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IFI27 GENE; IFI6 GENE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IRF7 GENE; IRF9 GENE; LOADING DRUG DOSE; MAEL GENE; MAGEB2 GENE; OVARY CANCER; PHARMACOGENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; EPIGENETICS; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

AZACITIDINE; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA, NEOPLASM; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS;

EID: 84896820241     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1782     Document Type: Article

References (37)

1. Baylin SB and Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nature reviews Cancer. 2011; 11(10):726-734.
2. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC and Pazdur R. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(10):3604-3608.
3. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer discovery. 2011; 1(7):598-607.
4. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer research. 2012; 72(9):2197-2205.
5. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, et al. Alterations of immune response of nonsmall cell lung cancer with Azacytidine. Oncotarget. 2013.
6. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer cell. 2012; 21(3):430-446.
7. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545-15550.
8. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(15):8681-8686.
9. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS genetics. 2007; 3(9):1709-1723.
10. Jeschke J, Van Neste L, Glockner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, et al. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics: official journal of the DNA Methylation Society. 2012; 7(7):701-709.
11. Nita Ahuja HE, Stephen B. Baylin. Harnessing the potential of epigenetic therapy to target solid tumors. Journal of Clinical Investigation. 2014; 124(1).
12. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Moller A, Smyth MJ, Anderson RL, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature medicine. 2012.
13. Platanias LC. Mechanisms of type-I-and type-II-interferonmediated signalling. Nature reviews Immunology. 2005; 5(5):375-386.
14. Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S and Schlom J. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer research. 1984; 44(8):3208-3214.
15. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D and Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Molecular pharmacology. 2004; 65(1):18-27.
16. James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM and Karpf AR. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics: official journal of the DNA Methylation Society. 2013; 8(8):849-863.
17. Karpf AR, Bai S, James SR, Mohler JL and Wilson EM. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Molecular cancer research: MCR. 2009; 7(4):523-535.
18. Akers SN, Odunsi K and Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future oncology. 2010; 6(5):717-732.
19. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, et al. CTdatabase: a knowledgebase of high-throughput and curated data on cancer-testis antigens. Nucleic acids research. 2009; 37(Database issue):D816-819.
20. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Borresen-Dale AL, Olopade OI and Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast cancer research and treatment. 2012; 133(3):865-880.
21. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capella G, Salazar R, Orphanides G, Wessels LF, Bernards R, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. International journal of cancer Journal international du cancer. 2013; 134(3):552-562.
22. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J and Birrer MJ. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer research. 2008; 68(13):5478-5486.
23. Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D, Collisson E, Zhu J, Yegnasubramanian S, Matsui W and Baylin SB. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome research. 2012; 22(5):837-849.
24. Schreiber RD, Old LJ and Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-1570.
25. Topalian SL, Weiner GJ and Pardoll DM. Cancer immunotherapy comes of age. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(36):4828-4836.
26. Connolly RM JR, Zahnow CA, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting J, Brufsky AM, Piekarz R, Ahuja N, Somlo G, Garcia AA, Baylin SB, Davidson NE, Stearns V. A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. AACR Annual Meeting, 2013 Washington, DC. 2013; (Abs 4666).
27. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology. 1974; 30(5):405-422.
28. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacology & therapeutics. 1995; 65(1):19-46.
29. Cihak A, Weiss JW and Pitot HC. Effects of 5-azacytidine on hepatic polyribosomes and maturation of ribosomal RNA. Acta biologica et medica Germanica. 1974; 33(5-6):859-865.
30. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011; 121(7):2750-2767.
31. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Flejou JF, Benchimol D, Berger A, Lagarde A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS medicine. 2013; 10(5):e1001453.
32. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of clinical investigation. 2013; 123(1):517-525.
33. Mohammad HP, Cai Y, McGarvey KM, Easwaran H, Van Neste L, Ohm JE, O'Hagan HM and Baylin SB. Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer research. 2009; 69(15):6322-6330.
34. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R and Pili R. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(15 Pt 1):4538-4546.
35. (2011). R: A Language and Environment for Statistical Computing. (Vienna, Austria: R Development Core Team).
36. G S. (2005). Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. (New York: Springer), pp. 397-420.
37. Chiappinelli KB, Haynes BC, Brent MR and Goodfellow PJ. Reduced DICER1 elicits an interferon response in endometrial cancer cells. Molecular cancer research: MCR. 2012; 10(3):316-325.